GleamWall
中文EN

CMPX Compass Therapeutics, Inc.

Biological Products, (No Diagnostic Substances) · Nasdaq · SEC CIK 1738021 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY—
TTM net income YoY-31.2%
TTM EPS YoY—
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—

Returns

ROE-49.0%
ROA-42.6%
ROIC (approx.)-56.2%
Asset turnover—

Leverage & solvency

Liabilities / assets18.3%
Debt / equity0.00x
Current ratio6.79x
Interest coverage—

Cash quality & payout

Operating cash flow / net income0.71x
Accruals ratio-12.2%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item 2026Q32026-09-302026Q22026-06-302026Q12026-03-312025Q4*2025-12-312025Q32025-09-302025Q22025-06-302025Q12025-03-312024Q4*2024-12-31
Income statement
Revenue———$0$0$0—$0
R&D expense$22.04M$19.58M$13.39M$13.67M$12.83M$16.41M$13.05M$13.04M
SG&A expense$6.76M$7.40M$6.91M$4.32M$2.99M$4.65M$4.91M$3.54M
Operating income-$28.80M-$26.98M-$20.30M-$17.99M-$15.82M-$21.07M-$17.97M-$16.57M
Pretax income——————-$16.63M—
Income tax——————$0—
Net income-$27.17M-$25.15M-$18.32M-$15.72M-$14.26M-$19.88M-$16.63M-$15.03M
EBITDA-$28.77M-$26.96M-$20.28M-$17.97M-$15.80M-$20.97M-$17.83M-$16.43M
EPS (basic)-0.15-0.13-0.10—-0.08-0.14-0.12—
EPS (diluted)————————
Weighted avg. shares (diluted)——————138.20M—
Balance sheet
Cash & equivalents$41.47M$35.45M$55.17M$30.64M$46.21M$22.86M$41.05M$43.48M
Short-term investments$121.59M$144.43M$139.52M$178.26M$173.68M$78.09M$71.59M$83.24M
Current assets$165.50M$180.89M$195.69M$209.82M$221.12M$106.19M$124.14M$132.75M
PP&E, net$402,000$324,000$169,000$102,000$119,000$131,000$102,000$353,000
Total assets$174.50M$190.17M$205.17M$219.59M$231.26M$116.70M$131.45M$140.40M
Current liabilities$24.37M$16.13M$10.28M$13.97M$12.41M$13.86M$14.90M$8.87M
Total liabilities$31.93M$24.12M$18.70M$22.80M$21.65M$23.49M$21.17M$15.17M
Shareholders' equity$142.57M$166.05M$186.47M$196.79M$209.61M$93.21M$110.28M$125.23M
Shares outstanding180.09M180.09M180.09M178.32M177.57M138.28M138.28M137.82M
Cash flow statement
Operating cash flow-$16.32M-$14.74M-$17.27M-$13.25M-$10.85M-$11.83M-$13.21M-$9.16M
Capital expenditure$106,000$176,000$82,000$0$7,000$0$18,000$0
Free cash flow-$16.42M-$14.91M-$17.35M-$13.25M-$10.86M-$11.83M-$13.23M-$9.16M
Investing cash flow$22.33M-$4.98M$38.43M-$3.38M-$95.16M-$6.36M$11.59M$15.37M
Financing cash flow$0$0$3.37M$1.06M$129.36M$0-$815,000-$94,000
Depreciation & amortization$28,000$21,000$15,000$17,000$19,000$100,000$140,000$140,000
Stock-based compensation$4.01M$4.82M$5.07M$1.82M$1.24M$2.79M$2.51M$2.24M

Free plan shows the latest 8 periods; Pro shows all 35 🔒

· This company does not report gross profit in XBRL.

· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.